Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 17/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | PDE9A | O76083 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE6C | P51160 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.37 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261737 | 0.92 | ADORA1 (0.43) | PDE5A | |
| SCHEMBL5261074 | 0.90 | PDE5A (0.36) | PDE5A | |
| SCHEMBL5830513 | 0.90 | ADORA3 (0.46) | PDE5AADORA2B | |
| SCHEMBL5261527 | 0.90 | PDE5A (0.45) | CA12CA9PDE5A | |
| SCHEMBL5261431 | 0.89 | PDE5A (0.52) | CA12CA9PDE5A | |
| SCHEMBL5261815 | 0.88 | PDE5A (0.40) | PDE5AADORA2B | |
| SCHEMBL5263080 | 0.87 | PDE5A (0.47) | CA12CA9PDE5A | |
| SCHEMBL5830512 | 0.86 | PDE5A (0.43) | PDE5AADORA2B | |
| SCHEMBL5260805 | 0.86 | PDE5A (0.42) | PDE5APDE6CPDE11A | |
| SCHEMBL5258961 | 0.85 | PDE5A (0.38) | CA12CA9PDE5APDE2APDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307458-B1 | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES | ALMIRALL LAB (ES) | 2007-10-03 | — | — | EP | claimed |
| US-20040019034-A1 | Pyrrolotriazolopyrimidinone derivatives | VIDAL JUAN BERNAT (ES) | 2004-01-29 | — | — | US | claimed |
| EP-1307458-B1 | PYRROLOTRIAZOLOPYRIMIDINONE DERIVATIVES | ALMIRALL LAB (ES) | 2007-10-03 | — | — | EP | disclosed |
| US-7060824-B2 | Pyrrolotriazolopyrimidinone derivatives | ALMIRALL PRODESFARMA, S.A. (ES) | 2006-06-13 | — | — | US | disclosed |
| US-20040019034-A1 | Pyrrolotriazolopyrimidinone derivatives | VIDAL JUAN BERNAT (ES) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019034-A1 | Pyrrolotriazolopyrimidinone derivatives | PDE5A, PDE3A, PDE2A | CA12 4544/4885CA9 884/4885PDE5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.